Click here to get full coverage on H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 - Yahoo Finance

H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30  Yahoo Finance

H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 - Yahoo Finance

Click here to get full coverage on BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A Look At 178% Potential Upside - DirectorsTalk Interviews

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A Look At 178% Potential Upside  DirectorsTalk Interviews

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A Look At 178% Potential Upside - DirectorsTalk Interviews

Click here to get full coverage on Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Volatility - simplywall.st

Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Volatility  simplywall.st

Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Volatility - simplywall.st

Click here to get full coverage on BCRX: ORLADEYO growth, Astria acquisition, and pipeline advances drive rare disease expansion - TradingView — Track All Markets

BCRX: ORLADEYO growth, Astria acquisition, and pipeline advances drive rare disease expansion  TradingView — Track All Markets

BCRX: ORLADEYO growth, Astria acquisition, and pipeline advances drive rare disease expansion - TradingView — Track All Markets

Click here to get full coverage on (BCRX) BioCryst Expects 2026 Revenue Range $635M to $660M, vs. FactSet Est of $660.5M - marketscreener.com

(BCRX) BioCryst Expects 2026 Revenue Range $635M to $660M, vs. FactSet Est of $660.5M  marketscreener.com

(BCRX) BioCryst Expects 2026 Revenue Range $635M to $660M, vs. FactSet Est of $660.5M - marketscreener.com

Click here to get full coverage on BCRX Forecasts FY26 ORLADEYO Revenue in Range of $625M-$645M - GuruFocus

BCRX Forecasts FY26 ORLADEYO Revenue in Range of $625M-$645M  GuruFocus

BCRX Forecasts FY26 ORLADEYO Revenue in Range of $625M-$645M - GuruFocus

Click here to get full coverage on Citizens Maintains BioCryst Pharmaceuticals (BCRX) Market Outperform Recommendation - Nasdaq

Citizens Maintains BioCryst Pharmaceuticals (BCRX) Market Outperform Recommendation  Nasdaq

Citizens Maintains BioCryst Pharmaceuticals (BCRX) Market Outperform Recommendation - Nasdaq

Click here to get full coverage on A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Undervalued Narrative Gains Traction - Yahoo Finance

A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Undervalued Narrative Gains Traction  Yahoo Finance

A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Undervalued Narrative Gains Traction - Yahoo Finance

Click here to get full coverage on Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround - Yahoo Finance

Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround  Yahoo Finance

Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround - Yahoo Finance

Click here to get full coverage on BCRX: ORLADEYO Sees Strong Revenue Growth in Q4 2025 - GuruFocus

BCRX: ORLADEYO Sees Strong Revenue Growth in Q4 2025  GuruFocus

BCRX: ORLADEYO Sees Strong Revenue Growth in Q4 2025 - GuruFocus

Click here to get full coverage on BioCryst Pharmaceuticals Inc (BCRX) Q3 2025 Earnings Call Highlights: Strong Orladeo Growth and ... - Yahoo Finance

BioCryst Pharmaceuticals Inc (BCRX) Q3 2025 Earnings Call Highlights: Strong Orladeo Growth and ...  Yahoo Finance

BioCryst Pharmaceuticals Inc (BCRX) Q3 2025 Earnings Call Highlights: Strong Orladeo Growth and ... - Yahoo Finance

Click here to get full coverage on BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?  Yahoo Finance

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Click here to get full coverage on BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock? - Yahoo Finance

BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?  Yahoo Finance

BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock? - Yahoo Finance

Click here to get full coverage on BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update - Yahoo Finance

BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update  Yahoo Finance

BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update - Yahoo Finance

Click here to get full coverage on BioCryst Pharmaceuticals (BCRX): Forecasts Call for 56.3% Annual Earnings Growth Heading Into Earnings Season - Yahoo Finance

BioCryst Pharmaceuticals (BCRX): Forecasts Call for 56.3% Annual Earnings Growth Heading Into Earnings Season  Yahoo Finance

BioCryst Pharmaceuticals (BCRX): Forecasts Call for 56.3% Annual Earnings Growth Heading Into Earnings Season - Yahoo Finance

Click here to get full coverage on Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX - Yahoo Finance

Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX  Yahoo Finance

Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX - Yahoo Finance

Click here to get full coverage on BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference - Yahoo Finance

BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference  Yahoo Finance

BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference - Yahoo Finance

Click here to get full coverage on BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... - Yahoo Finance

BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ...  Yahoo Finance

BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... - Yahoo Finance

Click here to get full coverage on BioCryst Pharmaceuticals (BCRX) Valuation in Focus Following Latest Pipeline and Business Updates - Yahoo Finance

BioCryst Pharmaceuticals (BCRX) Valuation in Focus Following Latest Pipeline and Business Updates  Yahoo Finance

BioCryst Pharmaceuticals (BCRX) Valuation in Focus Following Latest Pipeline and Business Updates - Yahoo Finance

Click here to get full coverage on BioCryst Pharmaceuticals, Inc. (BCRX) Q2 Revenue Soars 49%, Hits Record $163.4 Million on ORLADEYO Surge - Yahoo Finance

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 Revenue Soars 49%, Hits Record $163.4 Million on ORLADEYO Surge  Yahoo Finance

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 Revenue Soars 49%, Hits Record $163.4 Million on ORLADEYO Surge - Yahoo Finance

Click here to get full coverage on BioCryst Pharmaceuticals (BCRX) Is Up 8.0% After FDA Clears First Oral HAE Prophylaxis For Children - simplywall.st

BioCryst Pharmaceuticals (BCRX) Is Up 8.0% After FDA Clears First Oral HAE Prophylaxis For Children  simplywall.st

BioCryst Pharmaceuticals (BCRX) Is Up 8.0% After FDA Clears First Oral HAE Prophylaxis For Children - simplywall.st

Click here to get full coverage on BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance

BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates  Yahoo Finance

BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance

Click here to get full coverage on BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth  Yahoo Finance

BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Click here to get full coverage on Stock Market Recap: Is BCRX stock affected by interest rate hikes - Watch List & AI Driven Stock Reports - moha.gov.vn

Stock Market Recap: Is BCRX stock affected by interest rate hikes - Watch List & AI Driven Stock Reports  moha.gov.vn

Stock Market Recap: Is BCRX stock affected by interest rate hikes - Watch List & AI Driven Stock Reports - moha.gov.vn

Click here to get full coverage on Insider Sale: Chief Legal Officer of $BCRX Sells 19,770 Shares - Quiver Quantitative

Insider Sale: Chief Legal Officer of $BCRX Sells 19,770 Shares  Quiver Quantitative

Insider Sale: Chief Legal Officer of $BCRX Sells 19,770 Shares - Quiver Quantitative

Click here to get full coverage on Liquidity Mapping Around (BCRX) Price Events - Stock Traders Daily

Liquidity Mapping Around (BCRX) Price Events  Stock Traders Daily

Liquidity Mapping Around (BCRX) Price Events - Stock Traders Daily

Click here to get full coverage on BioCryst Pharmaceuticals (BCRX) Losses Narrow, Profitable Growth Forecast Challenges Bearish Narratives - simplywall.st

BioCryst Pharmaceuticals (BCRX) Losses Narrow, Profitable Growth Forecast Challenges Bearish Narratives  simplywall.st

BioCryst Pharmaceuticals (BCRX) Losses Narrow, Profitable Growth Forecast Challenges Bearish Narratives - simplywall.st

Click here to get full coverage on Analysts Expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) To Breakeven Soon - simplywall.st

Analysts Expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) To Breakeven Soon  simplywall.st

Analysts Expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) To Breakeven Soon - simplywall.st

Click here to get full coverage on BioCryst Pharmaceuticals Stock (BCRX) Opinions on Q2 Revenue Surge and Conference Insights - Quiver Quantitative

BioCryst Pharmaceuticals Stock (BCRX) Opinions on Q2 Revenue Surge and Conference Insights  Quiver Quantitative

BioCryst Pharmaceuticals Stock (BCRX) Opinions on Q2 Revenue Surge and Conference Insights - Quiver Quantitative

Click here to get full coverage on $BCRX stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

$BCRX stock is down 8% today. Here's what we see in our data.  Quiver Quantitative

$BCRX stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on The Technical Signals Behind (BCRX) That Institutions Follow - Stock Traders Daily

The Technical Signals Behind (BCRX) That Institutions Follow  Stock Traders Daily

The Technical Signals Behind (BCRX) That Institutions Follow - Stock Traders Daily

Click here to get full coverage on Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results - Yahoo Finance

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results  Yahoo Finance

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results - Yahoo Finance

Click here to get full coverage on Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st

Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models  simplywall.st

Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st

Click here to get full coverage on BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Posts Mixed Q3 2025 Results, Beats on EPS But Misses Revenue - Chartmill

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Posts Mixed Q3 2025 Results, Beats on EPS But Misses Revenue  Chartmill

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Posts Mixed Q3 2025 Results, Beats on EPS But Misses Revenue - Chartmill

Click here to get full coverage on Aug Ideas: Is BCRX stock a defensive play in 2025 - CPI Data & Expert Curated Trade Setups - moha.gov.vn

Aug Ideas: Is BCRX stock a defensive play in 2025 - CPI Data & Expert Curated Trade Setups  moha.gov.vn

Aug Ideas: Is BCRX stock a defensive play in 2025 - CPI Data & Expert Curated Trade Setups - moha.gov.vn

Click here to get full coverage on Citizens reiterates Market Outperform rating on BioCryst Pharma stock By Investing.com - Investing.com Nigeria

Citizens reiterates Market Outperform rating on BioCryst Pharma stock By Investing.com  Investing.com Nigeria

Citizens reiterates Market Outperform rating on BioCryst Pharma stock By Investing.com - Investing.com Nigeria

Click here to get full coverage on BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?  Yahoo Finance

BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

Click here to get full coverage on Does BioCryst’s DCF and Sales Multiple Suggest a Bargain After Recent HAE Progress? - simplywall.st

Does BioCryst’s DCF and Sales Multiple Suggest a Bargain After Recent HAE Progress?  simplywall.st

Does BioCryst’s DCF and Sales Multiple Suggest a Bargain After Recent HAE Progress? - simplywall.st

Click here to get full coverage on BCRX: HC Wainwright Maintains Buy Rating, Raises Price Target to $32 | BCRX Stock News - GuruFocus

BCRX: HC Wainwright Maintains Buy Rating, Raises Price Target to $32 | BCRX Stock News  GuruFocus

BCRX: HC Wainwright Maintains Buy Rating, Raises Price Target to $32 | BCRX Stock News - GuruFocus

Click here to get full coverage on $250M Deal: BioCryst Divests European ORLADEYO Business at 5.4x Sales Multiple, Retains US Focus - Stock Titan

$250M Deal: BioCryst Divests European ORLADEYO Business at 5.4x Sales Multiple, Retains US Focus  Stock Titan

$250M Deal: BioCryst Divests European ORLADEYO Business at 5.4x Sales Multiple, Retains US Focus - Stock Titan

Click here to get full coverage on BioCryst: Blue Light Special In Small-Cap Biotech Aisle (NASDAQ:BCRX) - Seeking Alpha

BioCryst: Blue Light Special In Small-Cap Biotech Aisle (NASDAQ:BCRX)  Seeking Alpha

BioCryst: Blue Light Special In Small-Cap Biotech Aisle (NASDAQ:BCRX) - Seeking Alpha

Click here to get full coverage on BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Exploring A 174% Potential Upside - DirectorsTalk Interviews

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Exploring A 174% Potential Upside  DirectorsTalk Interviews

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Exploring A 174% Potential Upside - DirectorsTalk Interviews

Click here to get full coverage on BioCryst (Nasdaq: BCRX) gains FDA nod for 1st oral HAE prophylaxis, ages 2- - Stock Titan

BioCryst (Nasdaq: BCRX) gains FDA nod for 1st oral HAE prophylaxis, ages 2-  Stock Titan

BioCryst (Nasdaq: BCRX) gains FDA nod for 1st oral HAE prophylaxis, ages 2- - Stock Titan

Click here to get full coverage on BioCryst (Nasdaq: BCRX) to present at Jefferies London on Nov 19, 12:00 p.m. ET; webcast - Stock Titan

BioCryst (Nasdaq: BCRX) to present at Jefferies London on Nov 19, 12:00 p.m. ET; webcast  Stock Titan

BioCryst (Nasdaq: BCRX) to present at Jefferies London on Nov 19, 12:00 p.m. ET; webcast - Stock Titan

Click here to get full coverage on BioCryst stock holds steady as Cantor Fitzgerald reaffirms Overweight rating By Investing.com - Investing.com Nigeria

BioCryst stock holds steady as Cantor Fitzgerald reaffirms Overweight rating By Investing.com  Investing.com Nigeria

BioCryst stock holds steady as Cantor Fitzgerald reaffirms Overweight rating By Investing.com - Investing.com Nigeria

Click here to get full coverage on Precision Trading with Biocryst Pharmaceuticals Inc. (BCRX) Risk Zones - Stock Traders Daily

Precision Trading with Biocryst Pharmaceuticals Inc. (BCRX) Risk Zones  Stock Traders Daily

Precision Trading with Biocryst Pharmaceuticals Inc. (BCRX) Risk Zones - Stock Traders Daily

Click here to get full coverage on RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 - Yahoo Finance

RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13  Yahoo Finance

RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 - Yahoo Finance

Click here to get full coverage on BCRX: ORLADEYO growth, Astria acquisition, and Nevenabart launch drive profitability and pipeline momentum - TradingView — Track All Markets

BCRX: ORLADEYO growth, Astria acquisition, and Nevenabart launch drive profitability and pipeline momentum  TradingView — Track All Markets

BCRX: ORLADEYO growth, Astria acquisition, and Nevenabart launch drive profitability and pipeline momentum - TradingView — Track All Markets

Click here to get full coverage on The Truth About BioCryst Pharmaceuticals (BCRX): Hidden Gem Stock or Total Trap? - AD HOC NEWS

The Truth About BioCryst Pharmaceuticals (BCRX): Hidden Gem Stock or Total Trap?  AD HOC NEWS

The Truth About BioCryst Pharmaceuticals (BCRX): Hidden Gem Stock or Total Trap? - AD HOC NEWS

Click here to get full coverage on New Analyst Forecast: $BCRX Given $20.0 Price Target - Quiver Quantitative

New Analyst Forecast: $BCRX Given $20.0 Price Target  Quiver Quantitative

New Analyst Forecast: $BCRX Given $20.0 Price Target - Quiver Quantitative

Click here to get full coverage on New Analyst Forecast: $BCRX Given $18.0 Price Target - Quiver Quantitative

New Analyst Forecast: $BCRX Given $18.0 Price Target  Quiver Quantitative

New Analyst Forecast: $BCRX Given $18.0 Price Target - Quiver Quantitative

Click here to get full coverage on Price-Driven Insight from (BCRX) for Rule-Based Strategy - Stock Traders Daily

Price-Driven Insight from (BCRX) for Rule-Based Strategy  Stock Traders Daily

Price-Driven Insight from (BCRX) for Rule-Based Strategy - Stock Traders Daily

Click here to get full coverage on BioCryst Updates ORLADEYO Revenue Outlook and Guidance - TipRanks

BioCryst Updates ORLADEYO Revenue Outlook and Guidance  TipRanks

BioCryst Updates ORLADEYO Revenue Outlook and Guidance - TipRanks

Click here to get full coverage on BioCryst (BCRX) Adjusts 2025 Financial Projections for ORLADEYO - GuruFocus

BioCryst (BCRX) Adjusts 2025 Financial Projections for ORLADEYO  GuruFocus

BioCryst (BCRX) Adjusts 2025 Financial Projections for ORLADEYO - GuruFocus

Click here to get full coverage on BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ) - Seeking Alpha

BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ)  Seeking Alpha

BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ) - Seeking Alpha

Click here to get full coverage on BioCryst stock gains on sale of EU Orladeyo business (BCRX) - Seeking Alpha

BioCryst stock gains on sale of EU Orladeyo business (BCRX)  Seeking Alpha

BioCryst stock gains on sale of EU Orladeyo business (BCRX) - Seeking Alpha

Click here to get full coverage on BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update  GlobeNewswire

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Click here to get full coverage on 71,400 RSUs and 36,700 Stock Options: BioCryst's Latest Employee Compensation Package Details - Stock Titan

71,400 RSUs and 36,700 Stock Options: BioCryst's Latest Employee Compensation Package Details  Stock Titan

71,400 RSUs and 36,700 Stock Options: BioCryst's Latest Employee Compensation Package Details - Stock Titan

Click here to get full coverage on BioCryst Pharmaceuticals to Acquire Astria Therapeutics, Expanding HAE Portfolio with Navenibart in $920 Million Deal - Quiver Quantitative

BioCryst Pharmaceuticals to Acquire Astria Therapeutics, Expanding HAE Portfolio with Navenibart in $920 Million Deal  Quiver Quantitative

BioCryst Pharmaceuticals to Acquire Astria Therapeutics, Expanding HAE Portfolio with Navenibart in $920 Million Deal - Quiver Quantitative

Click here to get full coverage on BioCryst Pharmaceuticals Completes $250 Million Sale of European ORLADEYO Business to Neopharmed Gentili - Quiver Quantitative

BioCryst Pharmaceuticals Completes $250 Million Sale of European ORLADEYO Business to Neopharmed Gentili  Quiver Quantitative

BioCryst Pharmaceuticals Completes $250 Million Sale of European ORLADEYO Business to Neopharmed Gentili - Quiver Quantitative

Click here to get full coverage on BioCryst (BCRX) Awards Stock Options and RSUs to New Employees - GuruFocus

BioCryst (BCRX) Awards Stock Options and RSUs to New Employees  GuruFocus

BioCryst (BCRX) Awards Stock Options and RSUs to New Employees - GuruFocus

Click here to get full coverage on BioCryst (Nasdaq: BCRX) grants 30,700 RSUs under Nasdaq Listing Rule 5635(c)(4) - Stock Titan

BioCryst (Nasdaq: BCRX) grants 30,700 RSUs under Nasdaq Listing Rule 5635(c)(4)  Stock Titan

BioCryst (Nasdaq: BCRX) grants 30,700 RSUs under Nasdaq Listing Rule 5635(c)(4) - Stock Titan

Click here to get full coverage on BioCryst Raises Price of Key ORLADEYO Treatment - TipRanks

BioCryst Raises Price of Key ORLADEYO Treatment  TipRanks

BioCryst Raises Price of Key ORLADEYO Treatment - TipRanks

Click here to get full coverage on BioCryst Pharmaceuticals raises US price of Orladeyo to $48,487.92 per pack - Investing.com Nigeria

BioCryst Pharmaceuticals raises US price of Orladeyo to $48,487.92 per pack  Investing.com Nigeria

BioCryst Pharmaceuticals raises US price of Orladeyo to $48,487.92 per pack - Investing.com Nigeria

Click here to get full coverage on BioCryst: ORLADEYO Powers Profitability Amidst Rising HAE Competition (NASDAQ:BCRX) - Seeking Alpha

BioCryst: ORLADEYO Powers Profitability Amidst Rising HAE Competition (NASDAQ:BCRX)  Seeking Alpha

BioCryst: ORLADEYO Powers Profitability Amidst Rising HAE Competition (NASDAQ:BCRX) - Seeking Alpha

Click here to get full coverage on BioCryst Pharmaceuticals Announces Early Termination of HSR Waiting Period for Astria Therapeutics Acquisition - Quiver Quantitative

BioCryst Pharmaceuticals Announces Early Termination of HSR Waiting Period for Astria Therapeutics Acquisition  Quiver Quantitative

BioCryst Pharmaceuticals Announces Early Termination of HSR Waiting Period for Astria Therapeutics Acquisition - Quiver Quantitative

Click here to get full coverage on Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? - Stocktwits

Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today?  Stocktwits

BCRX

Price Chart

Key Statistics

Technicals

About BCRX

Latest News

H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 - Yahoo Finance

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A Look At 178% Potential Upside - DirectorsTalk Interviews

Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Volatility - simplywall.st

Advanced Charts

Top Gainers

Top Losers